[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of irbesartan and hydrochlorothiazide tablets in healthy adult Chinese subjects

考察空腹和餐后单次口服受试制剂厄贝沙坦氢氯噻嗪片（规格：150mg/12.5mg：每片含厄贝沙坦150mg，氢氯噻嗪12.5mg，宁波美诺华天康药业有限公司生产）与参比制剂厄贝沙坦氢氯噻嗪片（商品名：安博诺®；COAPROVEL®，规格：150mg/12.5mg：每片含厄贝沙坦150mg，氢氯噻嗪12.5mg，Sanofi Winthrop Industrie 生产），在中国健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评价两制剂的生物等效性。次要研究目的：评价空腹和餐后单次口服受试制剂和参比制剂在中国成年健康受试者中的安全性。

[Translation]

To investigate the relative bioavailability of the test preparation irbesartan hydrochlorothiazide tablets (specification: 150mg/12.5mg: each tablet contains 150mg irbesartan and 12.5mg hydrochlorothiazide, produced by Ningbo Menohua Tiankang Pharmaceutical Co., Ltd.) and the reference preparation irbesartan hydrochlorothiazide tablets (trade name: Ambron®; COAPROVEL®, specification: 150mg/12.5mg: each tablet contains 150mg irbesartan and 12.5mg hydrochlorothiazide, produced by Sanofi Winthrop Industrie) in healthy Chinese subjects after single oral administration on an empty stomach and after a meal, analyze the pharmacokinetic parameters of the two preparations, and evaluate the bioequivalence of the two preparations. Secondary study objectives: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese adult subjects after single oral administration on an empty stomach and after a meal.

Start Date06 Mar 2024

Sponsor / Collaborator

Hangzhou New Novartis Pharmaceutical Co., Ltd.

CTR20233514 / CompletedNot Applicable

单中心、随机、开放、两周期、交叉设计评价中国健康受试者单次空腹及餐后口服厄贝沙坦氢氯噻嗪片的人体生物等效性试验

[Translation] A single-center, randomized, open-label, two-period, crossover design study to evaluate the bioequivalence of fasting and fed oral irbesartan and hydrochlorothiazide tablets in healthy Chinese subjects

主要研究目的:以Sanofi Winthrop Industrie生产的厄贝沙坦氢氯噻嗪片（商品名：安博诺；规格：厄贝沙坦150mg和氢氯噻嗪12.5mg）为参比制剂，以江西施美药业股份有限公司研发的厄贝沙坦氢氯噻嗪片（规格：厄贝沙坦150mg和氢氯噻嗪12.5mg）为受试制剂，通过单中心、随机、开放、两周期、交叉设计的生物等效性试验来评价两种制剂在空腹及餐后条件下的生物等效性。次要研究目的:评估受试制剂厄贝沙坦氢氯噻嗪片和参比制剂安博诺在中国健康成年受试者中的安全性。

[Translation]

The main purpose of the study was to use irbesartan hydrochlorothiazide tablets (trade name: Ambono; specifications: irbesartan 150mg and hydrochlorothiazide 12.5mg) produced by Sanofi Winthrop Industrie as the reference preparation and irbesartan hydrochlorothiazide tablets (specifications: irbesartan 150mg and hydrochlorothiazide 12.5mg) developed by Jiangxi Shimei Pharmaceutical Co., Ltd. as the test preparation to evaluate the bioequivalence of the two preparations under fasting and postprandial conditions through a single-center, randomized, open, two-period, crossover design bioequivalence trial. Secondary purpose of the study was to evaluate the safety of the test preparation irbesartan hydrochlorothiazide tablets and the reference preparation Ambono in healthy adult subjects in China.

Start Date22 Dec 2023

Sponsor / Collaborator

Jiangxi Shimei Pharmaceutical Co., Ltd.

CTR20233900 / CompletedNot Applicable

厄贝沙坦氢氯噻嗪片人体生物等效性研究

[Translation] Study on the bioequivalence of irbesartan and hydrochlorothiazide tablets in healthy volunteers

主要目的：本试验旨在研究单次空腹和餐后口服广州白云山天心制药股份有限公司研制、生产的厄贝沙坦氢氯噻嗪片（厄贝沙坦150 mg/氢氯噻嗪12.5 mg）的药代动力学特征；以Sanofi Winthrop Industrie生产的厄贝沙坦氢氯噻嗪片（安博诺®，厄贝沙坦150 mg/氢氯噻嗪12.5 mg）为参比制剂，比较两制剂的药动学参数，评价两种制剂的生物等效性。次要目的：观察评估空腹和餐后状态条件下单次口服受试制剂厄贝沙坦氢氯噻嗪片和参比制剂厄贝沙坦氢氯噻嗪片（商品名：安博诺®）在中国健康受试者成年人群中的安全性。

[Translation]

Primary objective: This study aims to study the pharmacokinetic characteristics of irbesartan hydrochlorothiazide tablets (irbesartan 150 mg/hydrochlorothiazide 12.5 mg) developed and produced by Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. after single oral administration on an empty stomach and after a meal; irbesartan hydrochlorothiazide tablets (Anbono®, irbesartan 150 mg/hydrochlorothiazide 12.5 mg) produced by Sanofi Winthrop Industrie were used as the reference preparation to compare the pharmacokinetic parameters of the two preparations and evaluate the bioequivalence of the two preparations. Secondary objective: To observe and evaluate the safety of the test preparation irbesartan hydrochlorothiazide tablets and the reference preparation irbesartan hydrochlorothiazide tablets (trade name: Anbono®) in Chinese healthy adult subjects after a single oral administration on an empty stomach and after a meal.

Start Date07 Dec 2023

Sponsor / Collaborator

Guangzhou Baiyunshan Tianxin Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hydrochlorothiazide/Irbesartan

100 Translational Medicine associated with Hydrochlorothiazide/Irbesartan

100 Patents (Medical) associated with Hydrochlorothiazide/Irbesartan

Literatures (Medical) associated with Hydrochlorothiazide/Irbesartan

01 Jan 2021·American journal of translational researchQ3 · MEDICINE

Effect of Tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis.

Q3 · MEDICINE

Article

Author: Li, Qingzhen ; Huang, Yong ; Liu, Peipei ; Yuan, Hui ; Zhao, Jisheng

OBJECTIVE:

Investigate the effect of Tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis.

METHODS:

A total of 89 patients with chronic nephritis were randomly divided into a control group (44 cases, treated with irbesartan hydrochlorothiazide combined with dipyridamole) and an observation group (45 cases, treated with Tripterygium wilfordii polyglycoside tablets based on irbesartan hydrochlorothiazide and dipyridamole like the control group). Patients in both groups were treated for two months. The renal function, inflammatory factors, the proportion of T lymphocyte subsets, and 24 h urinary protein quantification (24 h Upro) of patients with hemodialysis were compared between the two groups before and after treatment. The occurrence of adverse reactions was recorded.

RESULTS:

SCR, BUN levels, 24 h Upro, serum hs-CRP, TNF-α, and IL-8 levels in the two groups after treatment were lower than those before treatment, and those of the observation group were lower than those of the control group (all P<0.05). After treatment, the CD4+ ratio and CD4+/CD8+ ratio of the two groups of patients increased, while the CD8+ ratio decreased. The changes in the observation group were greater than those in the control group (all P<0.05). There was no significant difference in the incidence of total adverse reactions between the two groups during treatment (P>0.05).

CONCLUSION:

Treatment combined with Tripterygium wilfordii polyglycosides can significantly alleviate the inflammatory state of patients with chronic glomerulonephritis, reduce the level of proteinuria, and improve renal function. Tripterygium wilfordii polyglycosides can improve immune function of the body and has high safety.

01 Feb 2014·Journal of pharmaceutical and biomedical analysisQ3 · MEDICINE

Low level drug product API form analysis – Avalide tablet NIR quantitative method development and robustness challenges

Q3 · MEDICINE

Article

Author: Pan, Duohai ; Crull, George ; Grosso, John ; Yin, Shawn

Avalide(@), a medication used for the treatment of hypertension, is a combination of Irbesartan, and Hydrochlorothiazide. Irbesartan, one of the active pharmaceutical ingredients (API) in Avalide products, exists in two neat crystalline forms: Form A and Form B. Irbesartan Form A is the API form used in a wet granulation for the preparation of Avalide tablets. The presence of the less soluble Irbesartan Form B in Avalide tablets may result in the slower dissolution. In this paper, we have presented our work on the method development, verification and challenges of quantitatively detecting, via NIR and ssNMR, very small amounts of Irbesartan Form B in Avalide tablets. As part of the NIR method development and qualification, limit of detection, linearity and accuracy were examined. In addition, a limited study of the robustness of the method was conducted and a bias in the level of Form B was correlated to the ambient humidity. ssNMR, a primary method for the determination of polymorphic composition, was successfully used as an orthogonal technique to verify the accuracy of the NIR method and added to the confidence in the NIR method. The speed and efficiency of the NIR method make it a suitable and convenient tool for routine analysis of Avalide tablets for Form B in a QC environment.

01 Jul 2005·Zhonghua xin xue guan bing za zhi

[The control rate of irbesartan/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension].

Article

Author: Chen, Jie ; Sun, Ning-ling ; Jing, Shan

OBJECTIVES:

To analyse the control rate of irbesartan/hydrochlorothiazide (HCTZ) combination tablets (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.

METHODS:

In this multi-center, open, single therapy trial, the enrolled patients aged 18-75 were treated with irbesartan/HCTZ combination tablets for 8 weeks. The initial dose comprised one tablet of irbesartan (150 mg)/HCTZ (12.5 mg) once a day during the first 2 weeks. If diastolic blood pressure was greater than 85 mm Hg at the end of the second or fourth weeks, irbesartan (300 mg)/HCTZ (12.5 mg) once a day or irbesartan (300 mg)/HCTZ (25 mg) once a day were added respectively.

RESULTS:

In 968 patients with mild to moderate hypertension enrolled, 920 patients were followed up for 8 weeks. (1) After 1 week of treatment, irbesartan/HCTZ combination tablets lowered systolic blood pressure by 11.87 mm Hg and diastolic blood pressure by 8.54 mm Hg (P < 0.01). After 8 weeks of treatment, the corresponding decreases were 21.97 mm Hg and 16.08 mm Hg, respectively (P < 0.01). (2) After 2, 4 and 8 weeks of treatment, 526, 703 and 769 patients reached blood pressure target (diastolic blood pressure less than 85 mm Hg). The control rates were 57.17%, 76.41% and 83.59%, respectively. (3) Among the 920 patients who completed the trial, 637 patients took irbesartan (150 mg)/HCTZ (12.5mg) once a day (69.24%), 211 patients took irbesartan (300 mg)/HCTZ (12.5 mg) once a day (22.93%), and 72 patients took irbesartan (300 mg)/HCTZ (25 mg) once a day (7.82%). (4) In the intention-to-treat analysis, no adverse reaction was observed in 903 patients (93.29% of the patients enrolled).

CONCLUSIONS:

When irbesartan/HCTZ combination regimen are used in the treatment of patients with mild to moderate primary hypertension, the proportion of patients reaching blood pressure target is high and adverse reactions are rare.

News (Medical) associated with Hydrochlorothiazide/Irbesartan

01 Aug 2023

·www.prnewswire.com

ZENTIVA PRESENTS STRONG ESG PROGRESS IN SUSTAINABILITY REPORT 2022

Prague, Aug. 1, 2023 /PRNewswire/ -- Zentiva is a leading manufacturer and supplier of high-quality and affordable medicines to more than 100 million people in Europe and beyond. With sustainability embedded into its business strategy, the company fulfilled its 2022 sustainability goals and implemented actions in 3 pillars: People, Partners and Planet. Continue Reading Zentiva publishes 2022 Sustainability Report Steffen Saltofte, CEO Zentiva: "Zentiva continues to make a significant contribution to public health in Europe. We are aware of our responsibility towards people, our partners and our planet. ESG (Environmental, Social, Governance) is helping us to navigate and fulfill our ambitions. Encouraging progress has been made in 2022 thanks to the engagement of our people and the cooperation and constructive dialogue with our partners and stakeholders." PEOPLE: We continued to strengthen the Diversity, Equity and Inclusion approach and signed the Diversity Charter in the Czech Republic joining Romania and Slovakia as members in their country as well. At the end of 2022, Zentiva is role modeling Diversity with a healthy gender balance across the organization, same time going beyond the gender topic to fuel our creativity and innovation by bringing teams together with different cultural, national and educational background, different life experience or abilities. With our #WeHelpOthers program our team engaged in 100 volunteering activities and community support projects. PARTNERS: Zentiva joined the UN Global Compact on human rights, labour, environment & anti-corruption. On its way forward, the 10 principles and the 17 Sustainability Development Goals were embedded. It was a year of strengthening our governance, starting from an updated Risk & Materiality Analysis, better best practice sharing and collaboration between different teams. This helped to further move on with the responsible sourcing programme, where we reviewed Top 80% of suppliers and actively discussing our common activities towards a sustainable future. PLANET: We translated our climate strategy into actions and delivered significant improvements in carbon reduction, energy and water efficiency and more efficient waste management. We continued as well our reforestation programme by planting another 100.000 trees. Zentiva's European Manufacturing Sites are sourced by 100 % renewable energy and we further invest to maximize the usage of solar panels in all our sites. We continue our carbon neutral roadmap that is targeting neutrality for scope 1 and scope 2 emissions by 2030. Ines Windisch, Head of HR, Communication & Sustainability: "It is for a reason that the "e" in Zentiva is green. We are looking back at a history of more than 500 years where Zentiva served people and communities with better healthcare. We want to ensure that for future generations, so that they can enjoy life as much as we do. And we know we have to act already today for a sustainable tomorrow." Zentiva's 2022 Sustainability Report discloses the non-financial topics referencing GRI standards and presents first time a verified carbon footprint analysis as well for Scope 3 emissions. The company presents an ambitious outlook for 2023, showing full commitment to further progress in all areas of ESG. Discover Zentiva's Sustainability Strategy and Goals and the actions implemented here. About Zentiva Zentiva is a producer of high-quality affordable medicines serving people in Europe and beyond. With a dedicated team of more than 4,800 people and a network of production sites - including flagship sites in Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people's daily healthcare needs. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on. Follow us on LinkedIn. Photo - Logo - SOURCE Zentiva

21 Mar 2023

·www.prnewswire.com

ZENTIVA COMMITS TO PLANT 1 MILLION TREES BY 2030

The company further strengthens its contribution to a healthier planet as part of their Sustainability strategy PRAGUE, March 21, 2023 /PRNewswire/ -- Zentiva today celebrates the International Day of Forests by committing to plant 1 million trees by 2030. Being a producer of high-quality and affordable medicines, Zentiva is generating carbon emissions and is aware of its impact on the environment. That is why the company committed to a strong sustainability program as part of its business strategy. Nick Haggar, CEO of Zentiva: "At Zentiva, we ensure medicines supply and more than 100 million people in Europe and beyond trust in our products. We have defined a comprehensive Sustainability Strategy and we have formalized our commitment to become carbon neutral for scope 1 and scope 2 by 2030. On top, we are further investing in programs to improve our efficiency in energy, water and waste management. I am proud that actions are real and not just paper commitments." Zentiva's Sustainability journey started back in 2019 by planting the first trees in Romania. Since then, the company has already planted more than 250.000 trees as part of its reforestation and offsetting program. The formalization of the 1-Million-Trees commitment is another milestone for the team. Ines Windisch, Head of HR, Communications & Sustainability: "Everyone in our company is involved in the Sustainability agenda as we believe that every small step and every small contribution counts. We are focusing our efforts not only on efficiency programs but as well on Biodiversity, supporting nature to recover and restore local ecosystems. There is just one Planet, and we want that future generations will enjoy their lives on Earth as much as we do." Zentiva has continued to significantly reduce its CO2 emissions during 2022 following on from a 16% reduction in 2021. It is important that all companies work to reduce their environmental impact and the Zentiva team is proud of the progress it is making. While the company's sustainability strategy is framed around 3 pillars: People, Partners and Planet, Zentiva will achieve the goal of carbon neutrality by focusing on reducing carbon emissions, sourcing from renewable energy, and increasing efficiency in energy, water and waste management. Click here to read more information about Sustainability at Zentiva. Logo - SOURCE Zentiva

02 Mar 2023

·www.prnewswire.com

DelveInsight Evaluates a Robust Diabetes Pipeline as 200+ Influential Pharma Players to Set Foot in the Domain

The prevalence of diabetes has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Diabetes and the growing research and development activities to develop novel therapies to treat diabetes to drive the market. The companies developing the potential therapies in the last stage of development include Eli Lilly and Company, Daewoong Pharmaceutical, Janssen Biotech, and several others. LAS VEGAS, March 2, 2023 /PRNewswire/ -- DelveInsight's ' Diabetes Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline diabetes therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the diabetes pipeline domain. Key Takeaways from the Diabetes Pipeline Report DelveInsight's diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for diabetes treatment. Key diabetes companies such as Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., and others are evaluating new diabetes drugs to improve the treatment landscape. Promising diabetes pipeline therapies in various stages of development include Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211, and others. In February 2023, Genprex, Inc. announced that data highlighting the potential of its gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the four-day International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023).These results were compelling as they demonstrated the potential for this gene therapy to create newly formed beta-like cells that can produce insulin. They also validated earlier studies of this approach in diabetic mouse models that showed restoration of normal blood glucose levels for several months. In February 2023, Provention Bio, Inc. announced the closing of the $35 million equity investment from Sanofi US under the previously announced Co-Promotion Agreement and Securities Purchase Agreement (the "Purchase Agreement").Pursuant to the Purchase Agreement, Sanofi purchased 2,712,497 shares of the Company's common stock, par value $0.0001 per share, at a price of $12.90 per share, representing a total investment of $35 million. In January 2023, iTolerance, Inc. announced it has entered into a Master Services Agreement (MSA) with the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine, for the advancement of its novel iTOL-100 platform technology as a potential cure for Type 1 Diabetes. In November 2022, Biocon Limited announced the signing of a semi-exclusive partnership agreement with Zentiva, a leading pharmaceutical company in Europe, for the commercialization of its vertically integrated, complex formulation, Liraglutide, a drug-device combination for the treatment and management of Type 2 diabetes and obesity.Under the terms of this agreement, Biocon is responsible for the manufacturing and supply of Liraglutide to Zentiva for its commercialization across 30 countries in Europe. Biocon also retained the right to commercialize this product under its own brand in the region. In November 2022, The US Food and Drug Administration (FDA) approved Provention Bio's biologics license application (BLA) for Tzield (teplizumab-mzwv) to treat type 1 diabetes (T1D) patients. The anti-CD3-directed antibody Tzield aims to delay the onset of Stage 3 T1D in adults and children aged eight years and above who are currently with stage 2 T1D. Request a sample and discover the recent advances in diabetes drug treatment @ Diabetes Pipeline Report The diabetes pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage diabetes drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the diabetes clinical trial landscape. Diabetes Overview Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or when the body does not use the insulin that is produced effectively. The vast majority of diabetes can be divided into two types: type 1 and type 2. Diabetes symptoms include polyuria, polydipsia, weight loss, sometimes accompanied by polyphagia and blurred vision. Chronic hyperglycemia may also cause growth impairment and susceptibility to certain infections. Diabetes long-term complications include retinopathy, which can lead to vision loss, nephropathy, which can lead to renal failure, peripheral neuropathy, which can lead to foot ulcers, amputations, and Charcot joints, and autonomic neuropathy, which can cause gastrointestinal, genitourinary, and cardiovascular symptoms. Diabetes is diagnosed through a thorough physical examination, medical history, and a battery of specialized tests. The A1C, or glycated hemoglobin test, is the primary test used to diagnose both type 1 and type 2 diabetes. Diabetes treatment typically consists of diet control, exercise, home blood glucose testing, oral medication, and insulin. Insulin is the primary treatment for type 1 diabetes, and people with type 2 diabetes can be treated with oral medications but may need insulin in some cases. Find out more about drugs for diabetes @ New Diabetes Drugs A snapshot of the Diabetes Pipeline Drugs mentioned in the report: Learn more about the emerging diabetes pipeline therapies @ Diabetes Clinical Trials Diabetes Therapeutics Assessment The diabetes pipeline report proffers an integral view of diabetes emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Diabetes Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Tumor necrosis factor alpha inhibitors, Glucagon receptor agonists, Cytotoxic T lymphocyte stimulants, Apoptosis inhibitors, Caspase inhibitors, Insulin-like growth factor binding protein inhibitors, Gene transference, Interleukin-10 expression modulators, CD40 antigen modulators Key Diabetes Companies: Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., and others. Key Diabetes Pipeline Therapies: Enavogliflozin, Golimumab, Dasiglucagon, ThermoStem, rGDF11, IMCY-0098, Insulin icodec, CagriSema, FDC Sema-OW GIP, SemaDapa FDC, ENT-001, AG019, JTT-662, AVT-001, AZD-0186, Cotadutide, LABP-111, VX-880, Encapsulated islet cell program, CPP-1X-T, REMD-477, AT-1501, LY 3209590, Orforglipron, LY3437943, Mazdutide, Peptide YY analogue agonist, GIPR agonist long acting, GIPR Agonist Long Acting II, LY 3493269, NNC0363-0845, Diamyd, ProTrans, VC-02, OPT101, Ladarixin, ILT-101, Stem Cell Educator Therapy, ORMD-0801, Golimumab, JAG301, SQZ TAC research program, VCTX 211 and others. Dive deep into rich insights for new drugs for diabetes treatment; visit @ Diabetes Medications Table of Contents For further information on the diabetes pipeline therapeutics, reach out @ Diabetes Drug Treatment Related Reports Type 1 Diabetes Market Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen , Novo Nordisk, Prevention Bio, among others. Type 1 Diabetes Epidemiology Forecast Type 1 Diabetes Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted type 1 diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diabetes Market Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others. Type 2 Diabetes Market Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others. Type 2 Diabetes Pipeline Type 2 Diabetes Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Blogs Evolution in Diabetes Management Diabetes Management and Care Increasing Prevalence of Diabetes Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

AcquisitionLicense out/in

100 Deals associated with Hydrochlorothiazide/Irbesartan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09DA04	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	EU	Sanofi Winthrop Industrie SA	14 Oct 1998
Essential Hypertension	IS	Sanofi Winthrop Industrie SA	14 Oct 1998
Essential Hypertension	LI	Sanofi Winthrop Industrie SA	14 Oct 1998
Essential Hypertension	NO	Sanofi Winthrop Industrie SA	14 Oct 1998
Hypertension	US	Sanofi-Aventis U.S. LLC	30 Sep 1997

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00708344 (ACTUAL, Pubmed)	Phase 4	Hypertension	833	irbesartan/hydrochlorothiazide (Early titration group)	hlkqmvrhxo(jngxisweov) = Serious adverse events were more frequent in E (2.5% vs 0.7%) pdlgujhtno (zbukwviwvs )	-	01 Dec 2011
				irbesartan/hydrochlorothiazide (Late titration group)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis